Telix Pharmaceuticals Ltd
TLX101-Px
glioma
Countdown
67days
FDA decision · Sep 11, 2026
What's at stake
The FDA's approval decision on TLX101-Px for glioma is due Sep 11, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 10h ago
“Telix has resubmitted its NDA in the U.S. with the additional clinical data and analysis as agreed with the FDA.”